SCHEMBL1965559

SCHEMBL1965559

COC(=O)c1c(O)c2cc(Br)cn2n(Cc2ccc(C(F)(F)F)cc2)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.42
EGLN1 Q9GZT9 2/20 0.39
EGLN2 Q96KS0 1/20 0.39
EGLN3 Q9H6Z9 1/20 0.39
MAPK10 P53779 4/20 0.37
ALDH1A1 P00352 2/20 0.37
USP2 O75604 1/20 0.37
NOTUM Q6P988 1/20 0.37
MAPK8 P45983 1/20 0.36
PPARA Q07869 1/20 0.36
KMT2A Q03164 2/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
MEN1 O00255 1/20 0.36
PARK7 Q99497 1/20 0.35
SRC P12931 1/20 0.35
PRKACA P17612 1/20 0.35
PRKACG P22612 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1965536 0.90 KDM4E (0.45) KDM4ESMN1; SMN2EGLN1EGLN2EGLN3
SCHEMBL1969661 0.86 KDM4E (0.42) KDM4ESMN1; SMN2EGLN1EGLN2EGLN3
SCHEMBL3730844 0.83 KDM4E (0.45) KDM4ESMN1; SMN2EGLN1EGLN2EGLN3
SCHEMBL1966780 0.78 MAPT (0.41) KDM4EMAPK10ALDH1A1USP2KMT2A
SCHEMBL1969294 0.78 HSP90AA1 (0.41) KDM4ESMN1; SMN2MAPK10ALDH1A1KMT2A
SCHEMBL1964099 0.76 HSP90B1 (0.41) KDM4ESMN1; SMN2ALDH1A1MAPK8KMT2A
SCHEMBL3725348 0.75 KDM4E (0.40) KDM4ESMN1; SMN2EGLN1EGLN2EGLN3
SCHEMBL1966356 0.74 AR (0.40) MAPK10ALDH1A1MAPK8KMT2AMEN1
SCHEMBL1968958 0.74 EGLN1 (0.65) EGLN1EGLN2EGLN3
SCHEMBL1966099 0.73 KDM4E (0.44) KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 KDM4E 471/4885SMN1; SMN2 3833/4885EGLN1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.